BUSINESS CONSULTING AGREEMENTBusiness Consulting Agreement • May 6th, 2021 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (the “Agreement”) is made and entered into by and between CytomX Therapeutics, Inc., a Delaware corporation, with an address at 151 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080, (“Company”) and, Charles Fuchs, M.D., M.P.H., an individual residing at the address set below (“Consultant”), effective as of April 1, 2021 (“Effective Date”).
AMENDMENT NO 2 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 6th, 2021 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Amendment Number 2 (the “Amendment No 2”), effective as of February 22, 2021 (the “Amendment No 2 Effective Date”) amends that certain Collaboration and License Agreement entered into as of May 23, 2014 (the “Collaboration Agreement”) by and between CYTOMX THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, having its principal place of business at 151 Oyster Point Blvd., Suite 400, South San Francisco, CA, 94080 (“CytomX”), and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York, USA 10154 (“BMS”), as amended by Amendment Number 1 to Extend Collaboration and License Agreement, dated as of March 17, 2017.
